• Home /
  • Research Grade Telisotuzumab vedotin (ADC)

Research Grade Telisotuzumab vedotin (ADC)

Synonyms:

ABBV-399, Teliso-V, antibody-drug conjugate (ADC)

Species:

Human

Cat. No.:

DHC34299B pdf (datasheet)

Quantity/Size:

5.0 mg

Price:

$6,325.00 BUY

Concentration:

1.0 mg/ml, lot specific

Description:

Telisotuzumab vedotin is an ADC consisting of a cMET-directed antibody and Monomethyl auristatin E (MMAE) that has recently obtained the breakthrough therapy designation (BTD) for the treatment of patients with c-Met overexpression, advanced/metastatic wild-type (WT) epithelial growth factor receptor (EGFR) non-squamous non-small cell lung cancer (sqNSCLC) that progressed during or after platinum-based chemotherapy.

Entrez Symbol:

MET

Uniprot Name:

Hepatocyte growth factor receptor

Uniprot ID:

P08581

Data PDF:

DHC34299

Purity:

> 90% by SEC

Specificity:

Human HGF receptor (Proto-oncogene c-Met)

Host Species:

Human

Isotype:

IgG1 Kappa light chain

Clone:

ABBV-399

Formulation:

Liquid

Purification:

Ion exchange chromatography

Application:

FS , Functional assay

Storage/Stability:

Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.